|
Press Releases |
|
 |
|
Thursday, August 22, 2024 |
|
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain |
Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Abeta) monoclonal antibody "Leqembi" (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
Wednesday, August 14, 2024 |
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates |
Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of Alzheimer's disease (AD). more info >> |
|
Tuesday, August 6, 2024 |
|
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation |
Eisai Co., Ltd. reconfirmed that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI (generic name:lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows. more info >> |
|
Wednesday, July 31, 2024 |
|
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 |
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually. more info >> |
|
Monday, July 29, 2024 |
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD). more info >> |
|
Thursday, July 25, 2024 |
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
Tuesday, July 23, 2024 |
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
Tuesday, July 16, 2024 |
|
エーザイ、ホスラブコナゾールのアジア・オセアニアにおけるライセンス契約を佐藤製薬と締結 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、抗真菌剤ホスラブコナゾールについて、真菌性疾患に対するアジア・オセアニアにおける開発および商業化に関するライセンス契約を佐藤製薬株式会社(本社:東京都、以下 佐藤製薬)と締結したことをお知らせします。 more info >> |
|
Friday, July 12, 2024 |
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
エーザイとバイオジェン、「レケンビ」(レカネマブ)がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)と バイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、 CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、ヒト化抗ヒト可溶性アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ®」(一般名:レカネマブ)について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Tradable Bits Powers Fan Engagement for Rugby Australia's Hosting of the Qatar Airways British & Irish Lions Men's Tour 2025
Jul 10, 2025 07:30 HKT/SGT
|
|
|
Hola Prime Unveils 'Hola Prime Futures' with Industry-First 1-Hour Withdrawals, Expands Forex Offering with MT4 Integration
Jul 10, 2025 07:00: JST
|
|
|
Hola Prime Unveils 'Hola Prime Futures' with Industry-First 1-Hour Withdrawals, Expands Forex Offering with MT4 Integration
Jul 10, 2025 07:00 HKT/SGT
|
|
|
SAPPE's Female CEO Takes the World Stage at the Global Summit of Women 2025 in Berlin, Germany
Jul 9, 2025 22:00 HKT/SGT
|
|
|
港股最大機械人IPO!國配認購超30倍 極智嘉正式在香港交易所主板掛牌上市
Jul 9, 2025 21:56 HKT/SGT
|
|
|
康诺思腾自主创新研发的手术机器人 成功于英国启动首轮临床试验
Jul 9, 2025 20:35 HKT/SGT
|
|
|
Cornerstone Robotics Launches First Clinical Evaluation of its Hong Kong-Developed Surgical Robotic System in UK
Jul 9, 2025 20:32 HKT/SGT
|
|
|
康諾思騰自主創新研發的手術機械人 成功於英國啟動首輪臨床試驗
Jul 9, 2025 20:32 HKT/SGT
|
|
|
Standard Chartered GBA Business Confidence Survey points to further tariff drag in H2
Jul 9, 2025 18:55 HKT/SGT
|
|
|
港股最大机器人IPO!国配认购超30倍 极智嘉正式在香港交易所主板挂牌上市
Jul 9, 2025 16:45 HKT/SGT
|
|
|
エーザイ、厚生労働省の中央社会保険医療協議会による「レケンビ」の費用対効果評価について
Jul 9, 2025 14:50: JST
|
|
|
Malaysia and France Strengthen Defence Industry Ties with Landmark MoU Signing
Jul 9, 2025 12:08 HKT/SGT
|
|
|
GMG Commencing Sales of G(R) Lubricant and Advancing Regulatory Approvals
Jul 9, 2025 09:00 HKT/SGT
|
|
|
"Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry" has been selected as a R&D project under K Program
Jul 8, 2025 20:30 JST
|
|
|
翼菲科技衝刺港股:輕工業機器人先鋒 全棧技術驅動商業化潛力可期
Jul 8, 2025 11:05 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|